Guggenheim Capital LLC Alkermes Plc. Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 57,359 shares of ALKS stock, worth $1.93 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
57,359
Previous 90,994
36.96%
Holding current value
$1.93 Million
Previous $2.55 Million
35.23%
% of portfolio
0.01%
Previous 0.02%
Shares
25 transactions
Others Institutions Holding ALKS
# of Institutions
376Shares Held
173MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$979 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$622 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$412 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$296 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$254 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.52B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...